2019企業影片_英文無字幕.mp4_000130.125[870x320]
在肺癌、胃癌及骨轉移病患的治療上具較明確的療效佐證。
  1. Adjuvant combination therapy with gemcitabine and autologous γδ T-cell transfer in patients with curatively resected pancreatic cancer. Cytotherapy. 2017 19(4):473-485
  2. Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer. Clin Exp Med 2017 17(1):19-31.
  3. CD27(-)CD45(+) γδ T cells can be divided into two populations, CD27(-)CD45(int) and CD27(-)CD45(hi) with little proliferation potential. Biochem Biophys Res Commun. 2016 478(3):1298-303.
  4. Improvement of Impaired Immunological Status of Patients with Various Types of Advanced Cancers by Autologous Immune Cell Therapy. Anticancer Res. 2015 35(8):4535-43.
  5. Myeloid molecular characteristics of human γδ T cells support their acquisition of tumor antigen-presenting capacity. Cancer Immunol Immunother. 2015 24
  6. Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer. Cancer Med. 2014 3(2):362-75.
  7. γδ T cell therapy for the treatment of non-small cell lung cancer. Transl Lung Cancer Res. 2014 3(1):23-33
  8. Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy. Int J Oncol 2014 45(5):1847-56
  9. Prospective evaluation of safety of immune-cell therapy for patients with various types of advanced cancer. Anticancer Res 2014 34(8):4601-7
  10. γδT細胞によるがん免疫治療。実験医学増刊 2013 31(12):185-9
  11. γδT細胞を⽤いたがん免疫治療。腫瘍内科 2013 12(2):204-213
  12. Vγ9Vδ2T細胞を⽤いたがん免疫治療。医学のあゆみ 2013 244(9):854-860
  13. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ- Cytotherapy 2013 15(4):481-91
  14. Expansion of human peripheral blood γδ T cells using zoledronate. J Vis Exp. 2011 9;(55).
  15. Adoptive Immunotherapy for Advanced Non-small Cell Lung Cancer Using Zoledronate-expanded γδT Cells: A Phase I Clinical Study. J Immunother 2011 34(2):202-11
  16. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors. Cytotherapy 2011 13:92-7
  17. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic slid tumors. Br J Cancer 2011 105(6):778–86
  18. γδ T-cell immunotherapy for lung cancer. Surg Today 2011 41(5):606-11
  19. 術後補助療法としての⾃⼰γδT細胞免疫治療。胆と膵 2011 9:893-8
  20. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gamma delta T cells. Eur J Cardiothorac
  21. Surg 2010 37(5):1191-7
  22. Clinical and immunological evaluation of zoledronate-activated Vγ9γδ T-cell based immunotherapy for patients with multiple myeloma. Exp Hematol. 2009 37(8):956-68
  23. Impact of culture medium on the expansion of T cells for immunotherapy. Cytotherapy 2009 11(7):936-46
  24. Zoledronate facilitates large-scale ex vivo expansion of functional gamma delta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 2008 10(8):842-56
  25. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs–rituximab and trastuzumab. Int J Cancer 2008 122(11):2526-34
  26. 腫瘍細胞とZoledronate共感作樹状細胞による活性化γδT細胞を介しての腫瘍抗原特異的CD8+T細胞の誘導上昇。細胞 2008 39:44-48 Chemotherapy and zoledronate sensitize solid tumor cells to Vgamma9Vdelta2 T cell cytotoxicity. Cancer Immunol Immunother. 2007 56(8):1285-97
  27. The therapeutic potential of immuno-cell therapy of cancer in combination with aminobisphosphonates. Anticancer Res. 2006 26(6A):3989-95